资讯

American Association of Individual Investors21 小时
Why Design Therapeutics, Inc.’s (DSGN) Stock Is Down 5.42%
Design Therapeutics, Inc.’s DSGN share price has dipped by 5.42%, which has investors questioning if this is right time to ...
生物通13 小时
探寻重症肌无力遗传密码：CHRNA1 与 CHRNB1 基因变异的关键作用
为探究抗乙酰胆碱受体抗体阳性重症肌无力（MG）的遗传因素，研究人员开展 CHRNA1 和 CHRNB1 基因相关研究。结果发现相关基因变异是欧洲人群 MG 尤其是晚发型 MG 的风险因素。该研究为 MG 遗传机制研究提供重要依据。
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological ...